The concept of traditional Chinese medicine is active! Many stocks closed with a limit of gains, with individual stocks rising 29 times in the past year

【Pharmaceutical Network Pharmaceutical Stock Market】Recently, affected by favorable policies, the concept of traditional Chinese medicine has been active
.
According to data from the Oriental Wealth Network Market Center, as of the close of trading on November 10, many stocks including Longjin Pharmaceutical, Kanghui Pharmaceutical, Jingjing Pharmaceutical, Zhongsheng Pharmaceutical, Panlong Pharmaceutical, etc.
closed with a price limit, and Huluwa, Dali Pharmaceutical, ST Kangmei, etc.
rose by more than 4%.

As of the close on November 10, Longjin Pharmaceutical rose to close at 14.
69 yuan, with a volume of 517,700, a turnover of 731 million, a turnover rate of 13.
00%, and a loss in price-earnings (TTM
).
It is worth mentioning that the stock has risen 29 times in
the past year.
According to the data, Longjin Pharmaceutical is a pharmaceutical company
engaged in the research and development, production and sales of modern traditional Chinese medicine and characteristic chemical generic drugs.
The company's main products are Longjin injection lamp anthocyanin, which is a high-purity traditional Chinese medicine lyophilized powder injection, the product has the effect of activating blood circulation and removing stasis, channeling and relieving pain, used for the treatment of cardiovascular and cerebrovascular diseases, mainly used for the treatment of stroke and its sequelae, coronary heart disease, angina
.
At the same time, the company has also increased its capital in Muya Agriculture, which grows industrial hemp on a large scale, and introduced external investment to establish Yunnan Longjin Kangyou Biopharmaceutical Company as a high-end chemical generic drug development platform
.
As of the close on November 10, Kanghui Pharmaceutical closed with a price of 24.
49 yuan, with a volume of 17,400, a turnover of 42.
63 million, a turnover rate of 1.
75%, and a price-to-earnings (TTM) of 78.
60
.
The analysis believes that the reason for the limit increase of Kanghui Pharmaceutical is traditional Chinese medicine + dental treatment + NMN
.
The company's main business is the research, development, production and sales of Chinese proprietary medicines, the company's main products are Kun Fukang capsules (tablets), compound double flower tablets, silver elimination granules, with laurel bone pain capsules, compound clear band perfusion solution, etc.
, at the same time, the company participates in Xi'an Boen Biotechnology Co.
, Ltd.
, its research and development and production of bracketless invisible appliances, has been on the market
.
In addition, the company once said on the interactive platform that its capital increase Hubei Klevi Biopharmaceutical Co.
, Ltd.
has the production technology of NMN-nicotinamide mononucleotide, and if the relevant production line is established in the future, NMN-nicotinamide mononucleotide
can be produced.
As of the close of trading on November 10, Jingjing Pharmaceutical closed with a quotation of 16.
26 yuan, with a volume of 1.
3948 million, a turnover of 2.
128 billion, a turnover rate of 17.
19%, and a price-to-earnings (TTM) of 65.
81
.
The analysis believes that the reason for the price limit of Jingjing Pharmaceutical is traditional Chinese medicine + pharmaceutical e-commerce + lithium battery
.
The company is mainly engaged in the research and development, production and sales of traditional Chinese proprietary medicine preparations, chemical APIs and intermediates, chemical pharmaceutical intermediates, Chinese medicinal materials and
Chinese medicine pieces, biopharmaceuticals, etc.
His grandson company Luhua Senxuan has dioxygen five ring products, the current production capacity of 6,000 tons of expansion project trial production is about to end, dioxide five ring is the electrolytic solvent
of lithium batteries.
In addition, the company is also actively expanding its e-commerce business
.
As of the close on November 10, Zhongsheng Pharmaceutical rose and closed, with a quotation of 35.
40 yuan, a volume of 760,400, a turnover of 2.
622 billion, a turnover rate of 10.
75%, and a price-to-earnings (TTM) of 135.
61
.
Zhongsheng Pharmaceutical Co.
, Ltd.
is an enterprise mainly engaged in the research and development, production and sales of proprietary Chinese medicines, chemical drugs, Chinese herbal medicines, Chinese herbal tablets, and chemical APIs, and its products involve ophthalmology, cardiovascular and cerebrovascular, respiratory, digestive and other therapeutic fields
.
On the news, a few days ago, Zhongsheng Pharmaceutical issued an announcement that the first-class innovative drug RAY1216 tablets developed by its subsidiary Zhongsheng Ruichuang obtained the ethical approval of the leader of the phase III clinical trial
.
In addition, its wholly-owned subsidiary, the broad-spectrum antibiotic rifampicin capsules, was "reviewed"
.
As of the close on November 10, Panlong Pharmaceutical rose to close, with a quotation of 48.
64 yuan, a volume of 225,400, a turnover of 1.
065 billion, a turnover rate of 41.
68%, and a price-to-earnings (TTM) of 43.
01
.
The company is an enterprise specializing in standardized planting, drug production, research and development, sales and pharmaceutical logistics of medicinal materials, and the company has developed medical device products
such as Panlong seven cold compress gel and Panlong seven nanometer quick sticker.
The analysis believes that the reason for the stock is traditional Chinese medicine + 3CL protease inhibitor development + medical devices
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.